Cellectar Biosciences Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cellectar Biosciences stock.
View analyst ratings for Cellectar Biosciences or view top-rated stocks.

Wall Street analysts have given Cellectar Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellectar Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Cellectar Biosciences.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.03.
View Cellectar Biosciences' earnings history.

Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLRB shares have decreased by 27.2% and is now trading at $1.31.
View which stocks have been most impacted by COVID-19.

Cellectar Biosciences's stock reverse split on the morning of Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

4 equities research analysts have issued 12 month price targets for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $5.50. On average, they expect Cellectar Biosciences' share price to reach $3.83 in the next twelve months. This suggests a possible upside of 192.6% from the stock's current price.
View analysts' price targets for Cellectar Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cellectar Biosciences include Spruce Biosciences (SPRB), Kezar Life Sciences (KZR), Xeris Pharmaceuticals (XERS), BELLUS Health (BLU), Clearside Biomedical (CLSD), Marker Therapeutics (MRKR), Oncternal Therapeutics (ONCT), Taiwan Liposome (TLC), Corbus Pharmaceuticals (CRBP), Kamada (KMDA), Hookipa Pharma (HOOK), Tricida (TCDA), Seelos Therapeutics (SEEL), BCTG Acquisition (BCTG) and Sol-Gel Technologies (SLGL).
View all of CLRB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Cellectar Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.69%), Silverarc Capital Management LLC (1.15%), Millennium Management LLC (0.47%), Geode Capital Management LLC (0.46%), GSA Capital Partners LLP (0.30%) and Squarepoint Ops LLC (0.26%). Company insiders that own Cellectar Biosciences stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends for Cellectar Biosciences.

CLRB stock was sold by a variety of institutional investors in the last quarter, including Silverarc Capital Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Cellectar Biosciences or view top insider-selling stocks.

CLRB stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, GSA Capital Partners LLP, Squarepoint Ops LLC, Geode Capital Management LLC, Northern Trust Corp, Creative Planning, and Envestnet Asset Management Inc.. Company insiders that have bought Cellectar Biosciences stock in the last two years include Dov Elefant, James V Caruso, Jarrod Longcor, and Stephen A Hill.
View insider buying and selling activity for Cellectar Biosciences or or view top insider-buying stocks.

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLRB stock can currently be purchased for approximately $1.31.

Cellectar Biosciences has a market capitalization of $69.07 million. The biopharmaceutical company earns $-15,090,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

Cellectar Biosciences employs 11 workers across the globe.

The official website for Cellectar Biosciences is www.cellectar.com.

Cellectar Biosciences is headquartered at 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]